News
VAXX
2.230
-1.76%
-0.040
Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference
DALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at the Can...
GlobeNewswire · 5d ago
Vaxxinity's Vaccine Candidate Shows Durable Cholesterol Lowering Activity In Animal Models
Vaxxinity Inc (NASDAQ: VAXX) announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates. The company also selected VXX-401 to pursue as its anti-PCSK9 vaccine candidate to treat hypercholesterolemia. Th...
Benzinga · 08/02 17:43
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
Results support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterolVXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company p...
GlobeNewswire · 08/02 12:00
Vaxxinity's VXX-401 Selected as Lead Vaccine Candidate to Treat High Blood Cholesterol After Demonstrating Reduced LDL Cholesterol in Monkeys
Vaxxinity's VXX-401 Selected as Lead Vaccine Candidate to Treat High Blood Cholesterol After Demonstrating Reduced LDL Cholesterol in Monkeys
MT Newswires · 08/02 10:42
Vaxxinity Preclinical Data Show Vaccine Candidates Can Target Tau Protein in Patients With Alzheimer's Disease
Vaxxinity Preclinical Data Show Vaccine Candidates Can Target Tau Protein in Patients With Alzheimer's Disease
MT Newswires · 08/01 13:42
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates
"Our findings show that specific forms of Tau can be targeted by vaccines with subsequent functional impact," said Justin Boyd, Ph.D., Director of Translational Science at Vaxxinity. "This preclinical
Benzinga · 08/01 12:25
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)
DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau prote...
GlobeNewswire · 08/01 12:00
Insiders Buy More Than $21M Of 3 Penny Stocks
U.S. stocks traded slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested ...
Benzinga · 06/22 17:26
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/22 12:55
Insider Buy: Vaxxinity
MT Newswires · 06/21 17:17
Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers' pack
Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Technologies (A...
Seekingalpha · 06/16 14:08
Vaxxinity to Participate at the Jefferies Healthcare Conference
DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will part...
GlobeNewswire · 06/02 11:00
FUV, ATNF and LOV among mid-day movers
Gainers: Tonix Pharmaceuticals Holding (TNXP) +60%. Helius Medical Technologies (HSDT) +40%. View (VIEW) +42%. Spark Networks (LOV) +32%. Regencell Bioscience Holdings (RGC) +21%. 180 Life Sciences (ATNF) +20%. Evelo Biosciences
Seekingalpha · 06/01 17:13
--Vaxxinity Shares Rally 17% Amid Moderate Trading Volume, Reaching Three-Week High
MT Newswires · 06/01 14:38
What Percentage Of Vaxxinity, Inc. (NASDAQ:VAXX) Shares Do Insiders Own?
Every investor in Vaxxinity, Inc. ( NASDAQ:VAXX ) should be aware of the most powerful shareholder groups. Generally...
Simply Wall St. · 05/12 13:31
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.
Benzinga · 05/11 16:25
Vaxxinity GAAP EPS of -$0.47, revenue of $0.17M
Vaxxinity press release (NASDAQ:VAXX): Q1 GAAP EPS of -$0.47. Revenue of $0.17M.
Seekingalpha · 05/09 11:52
BRIEF-Vaxxinity Reports First Quarter 2022 Financial Results
reuters.com · 05/09 11:51
55 Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Benzinga · 05/06 16:00
Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
DALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will parti...
GlobeNewswire · 05/05 11:00
More
Webull provides a variety of real-time VAXX stock news. You can receive the latest news about Vaxxinity, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VAXX
Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that seeks to improve access to treatments for a range of indications. Its pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas, including Alzheimer's Disease (AD), Parkinson's Disease (PD), migraine and hypercholesterolemia. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines. Its Anti-PCSK9 targets proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiac events.